Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

被引：2

作者：

Kurzrock, Razelle ^{[1
]}

Voorhees, Peter M. ^{[2
]}

Casper, Corey ^{[3
]}

Furman, Richard R. ^{[4
]}

Fayad, Luis ^{[1
]}

Lonial, Sagar ^{[5
]}

Borghaei, Hossein ^{[6
]}

Jagannath, Sundar ^{[7
]}

Sokol, Lubomir ^{[8
]}

Usmani, Saad ^{[9
]}

van de Velde, Helgi ^{[10
]}

Qin, Xiang ^{[11
]}

Qi, Ming ^{[11
]}

Cornfeld, Mark J. ^{[12
]}

van Rhee, Frits ^{[13
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

[5] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[7] St Vincents Comprehens Canc Ctr, New York, NY USA

[8] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[9] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[10] Janssen Res & Dev, Beerse, Belgium

[11] Ortho Biotech Oncol Res & Dev, Malvern, PA USA

[12] Ortho Biotech Oncol Res & Dev, Raritan, NJ USA

[13] Bon Secours St Francis Hlth Syst, Hematol Oncol, Greenville, SC USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

10.1182/blood.V118.21.3959.3959

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：1693 / 1693

页数：1

共 50 条

[31] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Jones, Jeffrey A.
Benson, Don M., Jr.
Flynn, Joseph M.
Porcu, Pierluigi
Lustberg, Mark E.
Phelps, Mitchell
Poi, Ming
Chung, Diana
Quinion, Carl
Byrd, John C.
Wegener, William
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2011, 118 (21) : 1584 - 1584
[32] Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival
Tarella, Corrado
Gueli, Angela
Delaini, Federica
Rossi, Andrea
Barbui, Anna Maria
Gritti, Giuseppe
Boschini, Cristina
Caracciolo, Daniele
Bruna, Riccardo
Ruella, Marco
Gottardi, Daniela
Passera, Roberto
Rambaldi, Alessandro
PLOS ONE, 2014, 9 (09):
[33] Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Dirnberger-Hertweck, M.
Korolkiewicz, R.
Blum, K. A.
ANNALS OF ONCOLOGY, 2018, 29 (05) : 1266 - 1272
[34] Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-Cell non-hodgkin's lymphoma (NHL).
Advani, A
Giné, E
Gisselbrecht, C
Rohatiner, A
Rosen, S
Smith, M
Boni, J
Lejeune, C
Patel, H
BLOOD, 2005, 106 (11) : 71A - 71A
[35] Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma
Hess, Georg
Flohr, Thomas
Kolbe, Karin
Bonn, Sarah
Schuler, Martin
Derigs, Hans Guenter
Huber, Christoph
ANNALS OF HEMATOLOGY, 2006, 85 (11) : 769 - 779
[36] Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma
Georg Hess
Thomas Flohr
Karin Kolbe
Sarah Bonn
Martin Schuler
Hans Günter Derigs
Christoph Huber
Annals of Hematology, 2006, 85 : 769 - 779
[37] Long-term follow-up of taxol and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
Suh, G.
Khouri, I.
McLaughlin, P.
Romaguera, J.
Hagemeister, F.
Pro, B.
Samaniego, F.
Rodriguez, M.
Fayad, L.
Feng, L.
Younes, A.
ANNALS OF ONCOLOGY, 2008, 19 : 149 - 149
[38] Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
Suh, G. K.
McLaughlin, P.
Romaguera, J. E.
Hagemeister, F. B.
Pro, B.
Khouri, I. F.
Samaniego, F.
Rodriguez, M. A.
Fayad, L. E.
Feng, L.
Younes, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[39] Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth A.
Kuruvilla, John G.
Smith, Sonali M.
Porcu, Pierluigi
Maddocks, Kami J.
Ruppert, Amy S.
Byrd, John C.
Grever, Michael R.
Blum, Kristie A.
BLOOD, 2015, 126 (23)
[40] Induction of interleukin-6 by HCV core protein in patients with HCV-associated cryoglobulinemia and B-cell non-Hodgkin's lymphoma
Feldmann, G
Nattermann, J
Banasch, B
Nischalke, HD
Ahlenstiel, G
Kuntzen, T
Schulz, M
Woitas, R
Teschendorf, C
Schmiegel, W
Sauerbruch, T
Spengler, U
JOURNAL OF HEPATOLOGY, 2005, 42 : 157 - 157

← 1 2 3 4 5 →